ライフサイエンスコーパス: disease status

1 Randomisation was stratified by visceral disease status.

2 2 and FLT3 aberrant splicing correlated with disease status.

3 capacity and positively with atherosclerotic disease status.

4 tes, and high expression was correlated with disease status.

5 02) were associated with twin discordance in disease status.

6 on with the elevation of IL-1beta levels and disease status.

7 be useful as a minimally invasive marker of disease status.

8 most of the microbiome samples clustered by disease status.

9 nic Obstructive Lung Disease stage, and COPD disease status.

10 teria in Solid Tumors were applied to assess disease status.

11 ments being the most sensitive to changes in disease status.

12 two existing classifications of periodontal disease status.

13 can provide a continually updated record of disease status.

14 ividuals (n = 469) and the correlations with disease status.

15 ance on predicting both cognitive scores and disease status.

16 and can be regarded as an indirect effect to disease status.

17 Oligomeric Abeta was not a predictor of disease status.

18 stratified for hormone receptor and visceral disease status.

19 0 and MMP-9 are associated with radiographic disease status.

20 both circulating 25(OH)D concentrations and disease status.

21 es in environment or according to health and disease status.

22 ay serve as a clinically useful indicator of disease status.

23 identify variable interactions predictive of disease status.

24 that it may be a clinically useful marker of disease status.

25 lk may be useful as meaningful indicators of disease status.

26 and calcium supplements affects periodontal disease status.

27 ogic examination by a neurologist blinded to disease status.

28 Children were grouped according to disease status.

29 ic regression, allowing for interaction with disease status.

30 ctional and used self-reported insurance and disease status.

31 velopment of criteria for early diagnosis of disease status.

32 mal subset of SNPs with predicting power for disease status.

33 not reveal any variants associated with the disease status.

34 with the Mantel-Haenszel test stratified by disease status.

35 ading of fundus photographs to confirm their disease status.

36 ene expression correlated with the patients' disease status.

37 cific comorbidity index (HCT-CI), as well as disease status.

38 and myeloablative conditioning regardless of disease status.

39 reviewers who were blinded to each subject's disease status.

40 disease/treatment status and regional nodal disease status.

41 t of the patient's overall graft versus host disease status.

42 in paws of mice with CIA correlate with the disease status.

43 nteraction between SES, ancestry, and asthma disease status.

44 eek correlation of methylation patterns with disease status.

45 nd unrelated donor HCT, after adjustment for disease status.

46 vivo (40-kDa) is associated with periodontal disease status.

47 rait locus on a chromosome and its effect on disease status.

48 uture cardiovascular outcomes, regardless of disease status.

49 o misclassification of self-reported dry eye disease status.

50 prerequisites for accurate determination of disease status.

51 ce participation conditional on exposure and disease status.

52 which may ultimately be linked to divergent disease status.

53 ired by the study protocol for definition of disease status.

54 ive to whole-mouth assessment of periodontal disease status.

55 G) ranging from health to severe periodontal disease status.

56 atin C well matched follow-up chronic kidney disease status.

57 ial neoplasia grade 2 or higher [CIN2+]) for disease status.

58 ts that show significant association with AD disease status.

59 levels in skeletal muscle and differentiate disease status.

60 rhood SNPs show statistical association with disease status.

61 ulin use, renal function, and cardiovascular disease status.

62 early PD from healthy subjects and evaluate disease status.

63 e of relapse and provided a better marker of disease status.

64 supporting their remarkable contributions to disease status.

65 microbiome was not significantly affected by disease status.

66 .28 ng/mL were independently associated with disease status.

67 and Clostridiales, correlates strongly with disease status.

68 that were stratified by baseline periodontal disease status.

69 se of a radiosensitizing platinum agent, and disease status.

70 ve similar phenotypic effects independent of disease status.

71 as the alterations of fractal pattern during diseased statuses.

72 2.174-3.636; P < .001), HIV rather than AIDS disease status (1.377; 1.049-1.808; P = .02), and HIV cl

73 On the basis of investigators' assessment of disease status, 163 of 169 (96%) analysable patients in

74 3) in CSF allowed for reliable prediction of disease status 3 years from the time of sample collectio

75 DG PET to rank and localize single subjects' disease status according to PD-typical (PD vs. controls)

76 iomarkers with the most predictive power for disease status, achieving a 92% accurate classification

77 to basophil degranulation phenotypes and to disease status (active or inactive).

78 y was a strong inverse predictor of coronary disease status (adjusted odds ratio for coronary disease

79 patients attaining negative minimal residual disease status after remission induction, minimal residu

80 ith a permuted block procedure stratified by disease status, age, and geographical location.

81 n involvement and disease morbidity, current disease status and activity, past and current medication

82 nd adiponectin with mammographic density and disease status and assessed their prognostic effect on r

83 tudy we did not observe correlations between disease status and autophagic or lysosomal markers.

84 us factors such as cell type, cell cycle, or disease status and can change in response to a biochemic

85 tegies to further improve outcomes, although disease status and center expertise remain key component

86 evaluated the relationship between change in disease status and change in CRP using nonparametric tes

87 Investigator-determined disease status and clinical benefit were assessed every

88 apy-related or de-novo AML when adjusted for disease status and cytogenetics.

89 Vizsla pedigree dogs were stratified both on disease status and degree of relatedness to an affected

90 s not independent of age or minimal residual disease status and did not seem to be driven by an incre

91 Subjects were categorized by disease status and disability progression to determine t

92 re associated with phenotypic traits such as disease status and drug response.

93 ment in blood may be a useful determinant of disease status and efficacy of systemic therapy for mela

94 bal DNA methylation status as a biomarker of disease status and exposure to environmental toxicants,

95 odels the distribution of the test SNP given disease status and flanking marker genotypes.

96 ygous mutations in PGM3 that segregated with disease status and followed recessive inheritance.

97 iabetes mellitus (ITDM) have a more advanced disease status and higher atherothrombotic risk compared

98 ligation that was independent of HLA, AA, or disease status and included elevated plasma IL-1alpha, I

99 continuous variable, can be used to monitor disease status and might be useful as an intermediate en

100 ble, non-invasive technique to differentiate disease status and might provide a means to monitor and

101 ional hazard models according to periodontal disease status and number of teeth at baseline.

102 ty in risk stratification for cardiovascular disease status and outcomes.

103 e associated with clinical outcomes, such as disease status and patient survival.

104 g a relatively non-invasive means to monitor disease status and response to therapies.

105 amount of PTN correlated with the patients' disease status and response to treatment.

106 (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in c9ALS patients, and are l

107 Marker levels were correlated to disease status and survival.

108 ned by patient-reported global assessment of disease status and the Australian/Canadian Osteoarthriti

109 se models of neuromuscular disease to assess disease status and the effects of therapy.

110 ty of imaging for the accurate evaluation of disease status and the prediction of structural outcome.

111 us provide important clinical information on disease status and treatment efficacy in MS patients.

112 Patients were assessed regularly for disease status and treatment side-effects.

113 at baseline that controlled fully for basal disease status and treatment, the association of anger a

114 ssion was used to explore the association of disease status and various patient- and implant-related

115 riant (c.1907 G>A) in RBM20, segregated with disease status and was absent in unaffected internal ref

116 be necessary for the accurate evaluation of disease status and, in particular, for the definition of

117 ee that are associated with covariates (e.g. disease status); and (iii) assess the overall associatio

118 Younger age, latent disease status, and access to care at a regional center

119 Aggregated data per patient, disease status, and available measurements were assessed

120 associated with biological factors, such as disease status, and environmental factors, such as smoki

121 an ICD to 148 controls matched for age, sex, disease status, and family.

122 , and 10, leukocyte telomere length, chronic disease status, and frailty.

123 perform before and after treatment to assess disease status, and how to interpret the test results an

124 neuroimaging measures, cognitive scores and disease status, and ignore the important underlying inte

125 cardiovascular risk factors, cardiovascular disease status, and medication use, sequential quintiles

126 , lactate dehydrogenase at the time of ASCT, disease status, and method of stem-cell mobilization, we

127 o histologic grade, primary versus recurrent disease status, and response, determined with integrated

128 pt to physiological variables of blood flow, disease status, and tissue architecture by accommodating

129 olic blood pressure, baseline cardiovascular disease status, and total cholesterol (hazard ratio, 0.9

130 evelopment of novel compounds, assessment of disease status, and treatment efficacy.

131 lowed by linkage analysis with the redefined disease statuses, and whole genome and exome sequencing.

132 rrelation with rigorously confirmed cervical disease status, are sparse.

133 clinical chart audit, 2) current periodontal disease status as determined by clinical examination, an

134 bacteriaceae abundances were associated with disease status as expected, but also with treatment and

135 a and controls combined were associated with disease status, as well as negatively correlated with th

136 gene-locus-specific methylation alterations, disease status, asbestos burden, and survival in this ra

137 single cytokine) in combination with subject disease status (asthma or COPD).

138 keletal-related events, irrespective of bone disease status at baseline.

139 ulin use, renal function, and cardiovascular disease status at baseline.

140 reatment selection, and the determination of disease status at diagnosis without subjecting patients

141 e survival (PFS), overall survival (OS), and disease status at first restaging.

142 We estimated trends in disease status at presentation to care and at ART initia

143 Disease status at start of conditioning and the level of

144 term survival in Ph(+) ALL patients and that disease status at the time of HCT is an important predic

145 linical and/or radiographic determination of disease status at the time of last follow-up or recurren

146 Disease status at the time of transplantation is found i

147 ore, donor-recipient HLA-match, disease, and disease status at transplantation (factors associated wi

148 e from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gen

149 e and overall and leukemia-free survival was disease status at transplantation.

150 survival were significantly associated with disease status at transplantation.

151 Disease status before surgery was associated with surgic

152 ccording to the presence of minimal residual disease status before transplantation.

153 ng for age, sex, race/ethnicity, and chronic disease status, both uncorrected refractive error (odds

154 multimodal biomarkers could predict not only disease status but also cognitive function to help eluci

155 We propose a novel definition of disease status by specifying PFBC into genetic, clinical

156 of HIV-infected individuals, irrespective of disease status, can respond to TLR9 agonists and that th

157 f live kidney donors at risk for ADPKD whose disease status cannot be established with certainty on t

158 ulmonary evaluation within 6.5 years defined disease status; cases had FEV(1) less than lower limit o

159 measure of current QoL, is less sensitive to disease status changes but might be useful in characteri

160 d from bcl-2 PCR-detectable to -undetectable disease status, compared with 36% in the control group.

161 ules that were significantly correlated with disease status, composed primarily of genes associated w

162 nosis (< 30 x 10(9)/L vs > 30 x 10(9)/L) and disease status (CR1 vs > CR1).

163 ication of patient disease likelihood versus disease status defined by quantitative coronary angiogra

164 Disease status, determined in patients and relatives, re

165 Grade and disease status did not significantly affect histogram pa

166 ncreas, and prostate, makes determination of disease status difficult.

167 ve symptom control alone (1:1; stratified by disease status, disease site, duration of response to pr

168 andatory, taking into account comorbidities, disease status, donor selection, and effective nontransp

169 Logistic regression controlling for sex, disease status, donor type, and graft-versus-host diseas

170 d whether there is any change of periodontal disease status during and after pregnancy.

171 eronegative samples and delineate changes in disease status during the early stages of infection.

172 tcome and for longitudinal monitoring of the disease status during the maintenance period.

173 e-specified conceptual framework for health: disease status, effectiveness, safety, function, knowled

174 t lymphoma subtypes, with pretransplantation disease status emerging as the most important predictor

175 Subgroup analysis of end-stage renal disease status failed to reveal any association.

176 cumulative mortality by diabetes and kidney disease status for 15,046 participants in the Third Nati

177 ically characterized as to their periodontal disease status for serum levels of beta2-glycoprotein I-

178 y derived biomarkers to identify periodontal disease status from whole saliva and plaque biofilm.

179 cells (CTC) offer great potential to monitor disease status, gauge prognosis, and guide treatment dec

180 Controls were matched for disease, disease status, graft type, patient age, and transplanta

181 ut their phenotype and function in different disease status have not been well studied.

182 score; Fisher group; insulin use; infectious disease status; history of diabetes mellitus; and blood

183 ate (SDS)-soluble Abeta were able to predict disease status; however, SDS-soluble Abeta was a better

184 blood glucose value, insulin use, infectious disease status, Hunt-Hess classification score, Fisher g

185 ICAM5 showed the strongest association with disease status, ICAM1 is expressed at highest levels in

186 ay not directly underly the diagnosis of the disease status, if the associated quantitative trait is

187 s is underlined by the correct prediction of disease status in 94-97% of cases.

188 ay serve as a biomarker of prior and current disease status in AN.

189 ication, and autoantigen gene expression and disease status in ANCA-associated vasculitis, we measure

190 each of these traits were utlized along with disease status in bivariate linkage analysis.

191 eported that urinary ADAM12 is predictive of disease status in breast cancer patients and that ADAM12

192 I would be able to monitor and differentiate disease status in dystrophic muscle.

193 because cosegregation of rare variation and disease status in families can amplify association signa

194 how that MTV provides a sensitive measure of disease status in individual patients with multiple scle

195 an adjunct to standard methods of monitoring disease status in MBC.

196 isk for schizophrenia are also predictive of disease status in our data.

197 d with schizophrenia significantly predicted disease status in our sample (p = 5 x 10(-14)) and expla

198 However, assessing disease status in these animals has required time-consum

199 esents a new blood test to aid assessment of disease status in thyroid cancer follow-up.

200 phospholipase D3; Val232Met) segregated with disease status in two independent families and doubled r

201 therefore vital to have knowledge about the disease status in wild boar.

202 ies of factors associated with self-reported disease status, investigators may be well advised to con

203 he red module was negatively correlated with disease status, involving mostly nominally down-regulate

204 Monitoring disease status is difficult because of the lack of chara

205 esigned to compare cases and controls, where disease status is modeled as a function of RNA-Seq reads

206 Simple permutation of disease status is unacceptable for resolving this issue

207 ess acknowledgment, recognition of incurable disease status, knowledge of the advanced stage of the d

208 confounders, including demographic factors, disease status, lifestyle, and dietary intakes, higher p

209 across a variety of tissues under different disease status, making computational identification of e

210 c meta-immunological profile associated with disease status may contribute to our understanding of th

211 therapeutic failure in the minimal residual disease status may relate to an incomplete understanding

212 Randomization was stratified by disease status (measurable v nonmeasurable), prior bevac

213 Disease status measures accounted for 62-72% of the vari

214 Sociodemographic and disease status measures were examined as predictors of a

215 ting information regarding demographics, SLE disease status, medications, health care utilization, he

216 od with cardiometabolic function and chronic disease status more than 40 years later (in 2005-2007).

217 The phenotype can be univariate disease status, multivariate responses and even high-dim

218 r than the entire set of SNPs that modulated disease status (n = 14,751).

219 This SNP showed association with diabetes disease status (odds ratio [OR] 1.33, 95% CI 1.06-1.65,

220 was a significant predictor of C. neoformans disease status (odds ratio, 5.5; P = .03).

221 le information regarding the development and disease status of cells.

222 Antiviral efficacy was unrelated to the disease status of each animal, the protein from which th

223 umed that families were ascertained with the disease status of family members, and incorporation of t

224 ial identifiers, or to information about the disease status of individual subscribers (although these

225 g were carefully controlled, the periodontal disease status of patients known, periodontal disease me

226 ures relating to the biological condition or disease status of samples but it also can accurately det

227 of the drug dose and release kinetics to the disease status of the treated vessel.

228 able patient factors such as distribution of disease, status of the limb, comorbid conditions, and co

229 We assessed familial disease status on the basis of self-reported family hist

230 ents, as well as the impact of prior chronic disease status on these functional outcomes.

231 lates common DNA sequence variants to either disease status or incremental quantitative traits contri

232 e found no expression differences related to disease status or marker genotype for the other two gene

233 l polymorphisms within genes associated with disease status or phenotypic variation for a trait.

234 Biomarkers can be used to characterize disease status or predict disease behavior.

235 dels that predict either a categorical (i.e. disease status) or quantitative (i.e. cholesterol levels

236 estinal inflammation, longitudinally monitor disease status, or detect dysplastic changes in patients

237 cantly by gender, age (>/=40 vs. <40 years), disease status (OSD vs. control), order of administratio

238 his included questions related to treatment, disease status, other long-term conditions (LTCs), gener

239 tomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2 +/- 4.0 year

240 elated with PD and CAL regardless of patient disease status (P <0.001).

241 t, their prevalence correlated with coronary disease status (p = 0.017).

242 Stage was associated with celiac disease status (P = 0.018), and 78% of controls were sta

243 s non-activated vs and unknown) and visceral disease status (present vs absent).

244 CpG loci were independently associated with disease status (Q < 0.05).

245 alleles in African Americans, regardless of disease status (RA or control).

246 sensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic).

247 , busulfan, and melphalan group by sex, age, disease status, refractory to both proteasome inhibitors

248 In these cases, molecular analysis predicts disease status relatively directly.

249 Hence, defining disease status requires CT (or MRI), bone scan, metaiodo

250 ermine the effect of destructive periodontal disease status, severity, and progression on components

251 ression trait attributable to differences in disease status, sex, cell or tissue type, ancestry, gene

252 naturally infected cows, regardless of their disease status, specifically upregulated IL-10 and TGF-b

253 s careful consideration and understanding of disease status, stage of pregnancy, FDA classification a

254 ing age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on pos

255 f total cholesterol level or coronary artery disease status, statin therapy was associated with signi

256 ells are better correlates of Ag load (i.e., disease status) than of protection.

257 ta samples belong to different classes (e.g. disease status), the relationships may exhibit class-spe

258 imouse antibody response, and the enrollment disease status, the concordance index was 0.704.

259 n single-nucleotide polymorphisms (SNPs) and disease status, the logistic-regression model or general

260 ross a range of other patient assessments of disease status, the SLAQ had a response in the direction

261 often depend on participants' self-reported disease status to assess prevalence, incidence, and dise

262 dily available information about disease and disease status to categorize patients into 4 risk groups

263 se of sensitive techniques for assessment of disease status to inform evidence-based decisions on opt

264 fference in the age, laterality, disease, or disease status (treatment naive vs. previously treated)

265 or associations between genetic variants and disease status, typically via logistic regression.

266 based on acute kidney injury/chronic kidney disease status, underpinning the heterogeneity of fluid

267 In all participants, irrespective of their disease status, walking in Hyde Park led to an increase

268 Minimal residual disease status warrants consideration as an early measur

269 Disease status was assessed at baseline, 9 weeks, 18 wee

270 bel vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6.

271 Periodontal disease status was assessed by using the PI in the earli

272 as measured using a reporter cell assay, and disease status was assessed using the Disease Activity S

273 ffected," and "recovered." "Highly affected" disease status was associated with clinical complaints (

274 n from 8 CMR biomarkers; an index of chronic disease status was derived by assessing 8 chronic diseas

275 Atopic disease status was determined based on International Cla

276 The periodontal disease status was measured by the mean clinical attachm

277 The determination of minimal-residual-disease status was more informative.

278 The association with disease status was most obvious for Pi (odds ratio [OR]:

279 After 2 courses, disease status was nonactive (n = 2), better (n = 23), o

280 Celiac disease status was not associated with overall survival.

281 More severe disease status was predictive of increases in VLA diffic

282 Disease status was reassessed by CTC count (> or = 5 vs.

283 Peri-implant disease status was significantly associated with the sub

284 spouses, the concordance between the chronic disease status was striking.

285 onal grey matter density, age, education and disease status, we tested the association of regional gl

286 e predictive values for reported periodontal disease status were 56.2%, 78.8%, 32.8%, and 90.7%, resp

287 Health-related quality of life (HRQOL) and disease status were collected after 3 to 6 months.

288 At the patient level, only FasL and disease status were significantly correlated (P <0.05).

289 Performance score and disease status were the major predictors of outcome.

290 Survival and disease status were updated to February 2012.

291 to the stratification by, or enrichment for, disease status when testing associations between genetic

292 ians consider deprivation status, as well as disease status, when making decisions about treatments,

293 d CR1 expression levels were associated with disease status, where elevated expression levels were as

294 their relative information contribution to a disease status, which is different from the usual tag SN

295 change to a SNP might change an individual's disease status, which served as a calibration for each a

296 a set of possible temporal patterns of true disease status, whose prior probability was a function o

297 3 subgroups using discriminant analysis, or disease status with a binary assessment of sputum IL-1be

298 iography by improving the differentiation of disease status within a given radiographic grade, especi

299 e associations between the OCTA measures and disease status within each retinal layer.

300 Peripheral biomarkers related to disease status would be extremely valuable for assessing